000			02179 a2200625 4500
005			20250517184318.0
264		0	_c20180129
008			201801s 0 0 eng d
022			_a2045-7634
024	7		_a10.1002/cam4.1258 _2doi
040			_aNLM _beng _cNLM
100	1		_aIshiguro, Hiroshi
245	0	0	_aA phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). _h[electronic resource]
260			_bCancer medicine _cDec 2017
300			_a2909-2917 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntigens, CD34 _xblood
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCamptothecin _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Combinations
650	0	4	_aEndothelial Progenitor Cells _xdrug effects
650	0	4	_aFemale
650	0	4	_aGene Frequency
650	0	4	_aGlucuronosyltransferase _xgenetics
650	0	4	_aHeterozygote
650	0	4	_aHomozygote
650	0	4	_aHumans
650	0	4	_aIrinotecan
650	0	4	_aJapan
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Recurrence, Local
650	0	4	_aOxonic Acid _xadministration & dosage
650	0	4	_aPharmacogenetics
650	0	4	_aPharmacogenomic Variants
650	0	4	_aPhenotype
650	0	4	_aTegafur _xadministration & dosage
650	0	4	_aTreatment Outcome
700	1		_aSaji, Shigehira
700	1		_aNomura, Shogo
700	1		_aTanaka, Sunao
700	1		_aUeno, Takayuki
700	1		_aOnoue, Masahide
700	1		_aIwata, Hiroji
700	1		_aYamanaka, Takeharu
700	1		_aSasaki, Yasutsuna
700	1		_aToi, Masakazu
773	0		_tCancer medicine _gvol. 6 _gno. 12 _gp. 2909-2917
856	4	0	_uhttps://doi.org/10.1002/cam4.1258 _zAvailable from publisher's website
999			_c27782067 _d27782067